Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma.
Lin C, Luciani A, Itti E, El-Gnaoui T, Vignaud A, Beaussart P, Lin SJ, Belhadj K, Brugières P, Evangelista E, Haioun C, Meignan M, Rahmouni A. Lin C, et al. Among authors: belhadj k. Eur Radiol. 2010 Aug;20(8):2027-38. doi: 10.1007/s00330-010-1758-y. Epub 2010 Mar 23. Eur Radiol. 2010. PMID: 20309558
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Rosiñol L, Hebraud B, Oriol A, Colin AL, Ríos Tamayo R, Hulin C, Blanchard MJ, Caillot D, Sureda A, Hernández MT, Arnulf B, Mateos MV, Macro M, San-Miguel J, Belhadj K, Lahuerta JJ, Garelik MB, Bladé J, Moreau P. Rosiñol L, et al. Among authors: belhadj k. Front Oncol. 2023 Nov 2;13:1197340. doi: 10.3389/fonc.2023.1197340. eCollection 2023. Front Oncol. 2023. PMID: 38023148 Free PMC article.
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, Belhadj K, Brechignac S, Frenzel L, Chalopin T, Rey P, Schiano de Collela JM, Dib M, Caillot D, Macro M, Fontan J, Buisson L, Pavageau L, Roussel M, Manier S, Mohty M, Martinet L, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: belhadj k. Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4. Blood Cancer J. 2023. PMID: 37880285 Free PMC article. No abstract available.
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Diviné M, Tabah-Fisch I, Reyes F, Haioun C. El Gnaoui T, et al. Among authors: belhadj k. Ann Oncol. 2007 Aug;18(8):1363-8. doi: 10.1093/annonc/mdm133. Epub 2007 May 11. Ann Oncol. 2007. PMID: 17496309 Free article. Clinical Trial.
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.
Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, Copie-Bergman C, Belhadj K, El Gnaoui T, Gaillard I, Kuhnowski F, Meignan M, Haioun C. Dupuis J, et al. Among authors: belhadj k. Ann Oncol. 2009 Mar;20(3):503-7. doi: 10.1093/annonc/mdn671. Epub 2008 Dec 11. Ann Oncol. 2009. PMID: 19074215 Free article.
109 results